| Methods |
Quasi randomized
(alternate month strategy)
Single center trial
Blinding of randomization: no
Blinding of intervention: no
Complete follow‐up: yes
Blinding of outcome measurement: no |
| Participants |
Premature infants
Respiratory distress syndrome
Colfosceril palmitate (Exosurf Neonatal) n=64
Beractant (Survanta) n=57 |
| Interventions |
Beractant (Survanta) vs. colfosceril palmitate (Exosurf Neonatal) |
| Outcomes |
Days on assisted ventilation
Pulmonary hemorrhage
Mortality
Complications of prematurity |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
High risk |
Quasi randomized (alternate month strategy) |
| Allocation concealment (selection bias) |
High risk |
Blinding of randomization: no |
| Blinding (performance bias and detection bias)
All outcomes |
High risk |
Blinding of intervention: no |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
|
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
Blinding of outcome measurement: no |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
Complete follow‐up: yes |
| Selective reporting (reporting bias) |
Low risk |
|
